-

Butterfly iQ3 Ultrasound Featured in HBO Max’s The Pitt Episodes 12 and 13

Mainstream television use of Butterfly’s handheld ultrasound technology highlights its growing role in real-life patient care.

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (“Butterfly” or the “Company”) (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, shared that its Butterfly iQ3 ultrasound device was featured in Episodes 12 and 13 of the popular HBO Max medical drama The Pitt. The show has gained a significant following, including among healthcare professionals, given its realistic and compelling depiction of modern medical practices.

In the featured episodes, Butterfly Network’s handheld ultrasound devices are used extensively by the medical staff in a trauma triage setting. A pivotal episode showcases a mass casualty event in which the series lead Noah Wyle, playing the head of the ED, Dr. Michael "Robby" Robinavitch, orders the removal of traditional cart-based ultrasound equipment due to space limitations. In doing so, emphasizing the importance of mobile and efficient diagnostic tools like Butterfly. Throughout the episodes, the devices are utilized for critical assessments including EFAST exams, blood flow evaluations, and internal bleeding detection. In the latest episode, Butterfly is used to assess intracranial pressure, demonstrating its versatility in emergency and trauma care settings when used by both experienced and novice practitioners.

“This feature in The Pitt is a clear demonstration that point-of-care ultrasound is at a tipping point in healthcare,” commented Joseph DeVivo, President, Chief Executive Officer and Chairman of Butterfly Network. “What we’re seeing on screen is not just TV drama—this is happening across the country and globally. We have devices in all 100 of the top 100 U.S. health systems, and the adoption of this technology is accelerating at a pace that’s benefiting patients everywhere.”

Jennifer Huang, Butterfly Network’s Vice President of Marketing, added, “When we were asked by the production team to provide an iQ3 probe for the show, we didn’t know what to expect from an unpaid placement. The level of visibility and usage of our product in the series is a testament to the tremendous value of Butterfly’s technology and a demonstration that Butterfly is becoming the standard for handheld ultrasound. It's more than just a brand name; Butterfly is now a verb used among clinicians. It’s exciting to see how the healthcare community is increasingly recognizing its critical impact on patient care.”

The prominent placement of Butterfly iQ3 in The Pitt highlights the growing adoption of POCUS technology in real-world healthcare environments – a trend not just in trauma and emergency care but expanding across specialties. Butterfly’s portable ultrasound solutions are transforming the way medical professionals diagnose and treat patients at the point of care, empowering providers to deliver faster, more accurate assessments and improving patient outcomes.

For more information about Butterfly’s technology and its impact on healthcare, visit www.butterflynetwork.com.

About Butterfly Network

Butterfly Network, Inc. (NYSE: BFLY) is a healthcare company driving a digital revolution in medical imaging with its proprietary Ultrasound-on-Chip™ semiconductor technology and ultrasound software solutions. In 2018, Butterfly launched the world’s first handheld, single-probe, whole-body ultrasound system, Butterfly iQ. The iQ+ followed in 2020, and the iQ3 in 2024, each with improved processing power and performance by leveraging Moore’s Law. The iQ3 earned Best Medical Technology at the 2024 Prix Galien USA Awards, a prestigious honor and one of the highest accolades in healthcare. Butterfly’s innovations have also been recognized by Fierce 50, TIME’s Best Inventions and Fast Company’s World Changing Ideas, among other achievements.

Butterfly combines advanced hardware, intelligent software, AI, services, and education to drive adoption of affordable, accessible imaging. Clinical publications demonstrate that its handheld ultrasound probes paired with Compass™ enterprise workflow software, can help hospital systems improve care workflows, reduce costs, and enhance provider economics. With a cloud-based solution that enables care anywhere through next-generation mobility, Butterfly aims to democratize healthcare by addressing critical global healthcare challenges. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: https://www.butterflynetwork.com/choose-your-country.

Contacts

Butterfly Media:
Liz Learned
Head of Communications & PR, Butterfly
media@butterflynetwork.com

Butterfly Investors:
Heather Getz
Chief Financial and Operations Officer, Butterfly
investors@butterflynetwork.com

Butterfly Network, Inc.

NYSE:BFLY

Release Versions
$Cashtags

Contacts

Butterfly Media:
Liz Learned
Head of Communications & PR, Butterfly
media@butterflynetwork.com

Butterfly Investors:
Heather Getz
Chief Financial and Operations Officer, Butterfly
investors@butterflynetwork.com

Social Media Profiles
More News From Butterfly Network, Inc.

Butterfly Network to Report First Quarter 2026 Financial Results on April 30, 2026

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, announced that it will report first quarter 2026 financial results on Thursday, April 30, 2026, at 8:00 am ET. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and John Doherty, Executive Vice President and Chief Financial Officer, will host a conference call and webcast...

Butterfly Network Secures First FDA Clearance for Blind Sweep Ultrasound AI Tool, Marking a Major Stride for Women’s Health

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (“Butterfly,” “the Company”) (NYSE: BFLY), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced it has received clearance from the U.S. Food and Drug Administration (FDA) for a fully automated Gestational Age (GA) Tool integrated into its handheld ultrasound solution. This marks the first FDA-cleared blind-sweep ultrasound AI tool for estimating gestational age....

Butterfly Network Appoints David Horsley as Senior Vice President, Innovation – Butterfly Embedded™

NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of David Horsley, Ph.D. as Senior Vice President of Innovation – Butterfly Embedded™ to scale its Ultrasound-on-Chip™ co-development and licensing initiative. In this role, Dr. Horsley will lead strategy and go-to-market for Butterfly Embedded, overseeing new product...
Back to Newsroom